Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

HRMY vs AVDL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HRMY Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

HRMY Overall Winner 6-Pillar Tally: HRMY 5 – 1 AVDL Matrix Metrics: HRMY 6 – 4 AVDL

As of Nov 20, 2026, Harmony Biosciences Holdings, Inc. (HRMY) is the stronger overall head-to-head candidate over Avadel Pharmaceuticals plc Ordinary Share (AVDL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). HRMY carries a Unified Composite Score of 67.1/100 (BUY) at $32.59 (5.4x Forward P/E, 22.2% operating margin), whereas AVDL carries 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin).

  • Growth vs. Quality Trade-Off: HRMY earns the overall head-to-head edge with a stronger Unified Composite Score (67.1/100 BUY vs. AVDL 62.9/100 BUY) and 0.55β · 38% Vol risk profile, whereas AVDL leads top-line expansion (+54.9% YoY revenue growth, 0.07x PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: HRMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.4); meanwhile AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HRMY vs AVDL
HRMY NASDAQ Head-to-Head Winner
Harmony Biosciences Holdings, Inc. Common Stock
Pharmaceutical Preparations
$32.59
-1.18% 1D
Market Cap $1.9B
TTM Revenue $989M
Forward P/E 5.4x
Beta / 30D Vol 0.55β · 38% Vol
Unified Composite Score
67.1 / 100 BUY
Tech 80.0 Fund 74.0 Flow 70.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.1%), weak momentum, RSI 32
RSI-14: 32.4 · SMA20: $34.97 · SMA50: $37.77
AVDL NASDAQ
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
TTM Revenue $249M
Forward P/E 28.8x
Beta / 30D Vol 0.14β · 2% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50

6-Pillar Scorecard Institutional Category Breakdown (HRMY 5 – 1 AVDL)

Columns: Metric · HRMY · AVDL
1. Valuation Multiples HRMY
Forward P/E 5.4x 28.8x
Trailing P/E 10.9x 16.8x
PEG Ratio N/M 0.07x
EV / Revenue 1.5x 8.5x
2. Growth & Scale AVDL
Revenue Growth (YoY) +12.3% +54.9%
Earnings Growth (YoY) -6.9% +0.0%
TTM Revenue (USD) $989M $249M
Market Cap $1.9B $2.1B
3. Profitability & Quality HRMY
Gross Margin 74.0% 94.9%
Operating Margin 22.2% 2.5%
Net Profit Margin 18.1% -0.1%
Return on Equity (ROE) 18.7% -0.3%
4. Balance Sheet & Cash Flow HRMY
Cash Generation (TTM) $323M $2.7M EBITDA
Cash Flow Margin 32.6% 1.1% EBITDA Mgn
Net Cash / Leverage $498M Net Cash $1.01 Book/Sh · -0.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning HRMY
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 72.4% (11th %ile) 2.4% (<1st %ile)
Put/Call OI Skew 4.40x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat HRMY
OpEx & R&D Intensity 51.8% of Rev ($512M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HRMY (6) vs AVDL (4)
Institutional Metric HRMY AVDL Criterion Row Edge
Market Capitalization
Scale
$1.9B $2.1B Larger Scale AVDL
Trailing P/E Ratio
Valuation
10.9x 16.8x Lower Multiple HRMY
Forward P/E Ratio
Valuation
5.4x 28.8x Lower Multiple HRMY
Revenue Growth (YoY)
Growth
+12.3% +54.9% Higher Growth AVDL
Operating Margin (TTM)
Profitability
22.2% 2.5% Higher Margin HRMY
Net Profit Margin
Profitability
18.1% -0.1% Higher Margin HRMY
Return on Equity (ROE)
Capital Efficiency
18.7% -0.3% Higher ROE HRMY
52-Week Range Position
Momentum
38% ($26–$43) 89% ($6–$24) Stronger Trend AVDL
Beta / 30D Volatility
Risk Regime
0.55β · 38% Vol 0.14β · 2% Vol Lower Realized Risk AVDL
Unified Institutional Score
Composite Signal
67.1 / 100 (BUY) 62.9 / 100 (BUY) Higher Composite HRMY
Trailing 12M Revenue (USD)
Operating Scale
$989M $249M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
74.0% 94.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.5x EV/Rev 0.07x PEG · 8.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$323M ($498M Net Cash) $2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVDL +5.04 pp
HRMY: -4.39% · AVDL: +0.65%
3M Horizon HRMY +16.17 pp
HRMY: +9.85% · AVDL: -6.32%
6M Horizon HRMY +16.17 pp
HRMY: +9.85% · AVDL: -6.32%
1Y Horizon HRMY +16.17 pp
HRMY: +9.85% · AVDL: -6.32%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HRMY vs AVDL. Trailing 12-month operating profitability (HRMY 22.2% vs AVDL 2.5%) and valuation multiples (HRMY 5.4x vs AVDL 28.8x Forward P/E) are benchmarked directly in Pillar 4 below.

HRMY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$989M
Gross Margin74.0%
Op. Margin22.2%
ROE / Fwd P/E18.7% · 5.4x
AVDL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$249M
Gross Margin94.9%
Op. Margin2.5%
ROE / Fwd P/E-0.3% · 28.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HRMY CONSOLIDATION
114d in phase · OBV DISTRIBUTION
Current IV 72.4%
IV Percentile 11th %ile
Put/Call OI Skew 4.40x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact HRMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AVDL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 2.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVDL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $33.20 · IV 76.7%

HRMY Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($3,320)

Compare $3,320 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 76.7% ATM IV.

PUT-WALL MONTHLY INCOME Liq B

Dec 18 $30 / $27.5 Bull Put Spread

Sell 2x $30P · Buy 2x $27.5P · 30d

Net Entry $60 Credit
Max Credit / Yield +$60 (+13.6% RoM)
Max Risk / Buffer -10.5% Cushion ($440 Mgn)
5d Edge & Liquidity 78% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $35 / $30 Bear Put Spread

Buy 1x $35P · Sell 1x $30P · 30d

Net Entry $230 Debit
T+5d @ -5% Drop +$67 (+29%)
Max Risk / Buffer $230 Capped
5d Edge & Liquidity 0.8x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HRMY Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and 22.2% operating margin.
OpEx & R&D Reinvestment 51.8% of Rev ($512M)
90D Engineering Disclosures 0 Published
AVDL Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ HRMY vs AVDL Key Questions & Quantitative Answers

As of Nov 20, 2026, Harmony Biosciences Holdings, Inc. (HRMY) is the stronger overall head-to-head candidate over Avadel Pharmaceuticals plc Ordinary Share (AVDL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). HRMY carries a Unified Composite Score of 67.1/100 (BUY) at $32.59 (5.4x Forward P/E, 22.2% operating margin), whereas AVDL carries 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin). Growth vs. Quality Trade-Off: HRMY earns the overall head-to-head edge with a stronger Unified Composite Score (67.1/100 BUY vs. AVDL 62.9/100 BUY) and 0.55β · 38% Vol risk profile, whereas AVDL leads top-line expansion (+54.9% YoY revenue growth, 0.07x PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: HRMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.4); meanwhile AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AVDL leads the Growth & Scale pillar: HRMY posts +12.3% YoY revenue growth and -6.9% YoY earnings growth on $989M TTM revenue (74.0% gross margin, 22.2% operating margin), compared with AVDL at +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin). On trailing 12-month operating scale, HRMY generates $989M in USD-normalized revenue versus $249M for AVDL. In operating R&D and SG&A reinvestment, HRMY deploys 51.8% of Rev ($512M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVDL.

HRMY screens cheaper on headline valuation multiples. HRMY trades at 5.4x Forward P/E, 10.9x Trailing P/E, N/M PEG, and 1.5x EV/Revenue (32.6% FCF margin), whereas AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HRMY (18.7% ROE) versus AVDL (-0.3% ROE) capital efficiency.

In options market volatility and institutional positioning, HRMY carries 72.4% implied volatility (11th %ile, Compressed (<25th %ile)), a 4.40x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.55β · 38% Vol realized risk). By comparison, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.